How psychedelics may aid healing: science, evidence, and insights

TL;DR:

• Researchers think psychedelics may help through two processes: a short-term loosening of rigid brain activity and a longer window of neuroplasticity.
• In research protocols, preparation, a supervised setting and integration are treated as part of the treatment, not extras.
• Psilocybin and MDMA are investigational in the US. The evidence in serious illness is promising but early, and long-term safety data are limited.

Many people still carry a simple mental image of psychedelics: you take a substance, you have an intense experience, and something shifts. That picture leaves out most of what actually matters. Recent neuroscience reviews describe two biological processes, acute neural desynchronization and lasting neuroplasticity, as likely drivers of therapeutic change. But those processes don’t tell the whole story. In research settings, much depends on what happens before, during and after each session. This article lays out what we know, what is still emerging, and where the research stands for people living with chronic pain or serious illness.

Key Takeaways

1. 01

   Healing is both brain and context

   Research suggests biological change and the therapeutic setting both shape outcomes.

2. 02

   Structure is part of the protocol

   Preparation, supervision and integration are built into clinical trials to support benefit and reduce risk.

3. 03

   Promising evidence in serious illness

   Early trials in people with cancer reported reductions in depression and anxiety; larger studies are still needed.

4. 04

   Early signals for chronic pain

   Small pilot studies suggest feasibility, but the evidence is too limited for any recommendation.

5. 05

   Still investigational

   Psilocybin and MDMA are not FDA-approved; in the US they are available only in clinical trials.

How psychedelics work in the brain and mind

To understand how psychedelics might support healing, it helps to know what they do in the brain. Classic psychedelics, such as psilocybin and LSD, act mainly on serotonin 2A receptors found throughout the cortex. That sets off a cascade of changes researchers are still mapping, and two broad processes have become central to the scientific conversation.

The first is acute neural desynchronization. During a session, activity in the brain’s default mode network, a system linked to our ongoing inner narrative and sense of self, becomes temporarily disrupted, and regions that don’t usually communicate begin exchanging signals. Researchers think this may be part of why people describe a loosening of rigid thought patterns or a shift in perspective. It can also be disorienting, which is one reason trials provide close support.

The second process is subacute neuroplasticity. Laboratory and animal studies suggest that in the days and weeks after exposure, the brain may become more able to form new connections. Researchers sometimes describe this as a window in which therapy and reflection could have more effect, though how this translates to people is still being studied.

A key point from this research is that neither process alone is thought to produce healing. The brain changes may create an opportunity. Whether anything comes of it seems to depend on the person, the context and the support that follows.

Ketamine, which is used clinically today, works differently. It acts mainly on the glutamate system rather than serotonin 2A receptors, though it too is being studied for its effects on neuroplasticity.

Psychedelic-assisted therapy in research: structure and set and setting

Brain mechanisms are one side of the story. The other is the structure that research protocols build around each session, and the idea of set and setting.

“Set” refers to a person’s mindset going into a session: intentions, fears, psychological history and readiness. “Setting” refers to the physical and relational environment: the room, the presence of trained clinicians and the emotional safety of the space. Studies suggest that outcomes depend strongly on these non-drug factors.

In clinical trials, psychedelic-assisted therapy usually moves through three phases:

1. Preparation. Meetings with the study therapists to review medical history, discuss expectations and build trust before any session.
2. Supervised session. The compound is given in a controlled clinical environment with trained staff present throughout.
3. Integration. Follow-up sessions to make sense of what came up and connect it to daily life.

The same three-part structure is used in ketamine-assisted psychotherapy, which is available in clinics today: ketamine is prescribed off-label, with preparation, a guided session and integration with a therapist. You can read more about emotional healing integration and what a consultation process involves.

Current evidence: psychedelics for chronic pain and serious illness

What does the research show for the hardest situations? There are encouraging findings, with important caveats.

For people facing cancer and other life-threatening illness, some of the best-known early studies come from Johns Hopkins and NYU. Their randomized trials, published in 2016, reported that a psilocybin session with psychological support was followed by reductions in depression and anxiety, and many participants described a changed relationship to their diagnosis and to fear of death. These were small studies, and larger trials are still needed.

Here is a summary of where the evidence currently stands:

1. Depression in serious illness. Small randomized trials of psilocybin in people with cancer reported reductions in depressive symptoms that lasted for months in some participants.
2. Anxiety and existential distress. The same trials reported reductions in death-related anxiety and improvements in quality of life and sense of meaning.
3. Chronic pain. This is an early area of research. An open-label pilot study suggests feasibility and a possible benefit for certain chronic pain conditions, but without a control group and with few participants, it cannot show that the treatment works.
4. PTSD and addiction. MDMA-assisted therapy for PTSD reached phase 3 trials, but in August 2024 the FDA declined to approve it and asked for another phase 3 study. MDMA remains investigational. Psilocybin for alcohol use disorder is also being studied.
5. End-of-life distress. Reducing existential suffering near the end of life is one of the more consistent themes in early trials, but these studies are small and remain research.

None of these uses is FDA-approved. Psilocybin and MDMA are Schedule I substances under federal law and, outside a few state-regulated programs, the only medical route to them is a registered clinical trial. People living with serious illness who are struggling with depression, anxiety or existential distress do have options today, including psychotherapy, psychiatric care and palliative care, and for some, ketamine-assisted psychotherapy where clinically appropriate.

Reading about new approaches to healing can be hopeful. Informed expectations are part of responsible care.

Safety considerations, consent, and the limits of current knowledge

The promise of this research comes with real risks and open questions about safety and ethics.

One important and often overlooked issue is consent during an altered state. During a psychedelic experience, a person’s thinking and emotions are profoundly changed, which complicates consent for therapist contact and boundaries. Qualitative research with clinical researchers identifies this as an active ethical concern, and well-run studies address it explicitly before any session.

Several other gaps deserve honest acknowledgment:

• Long-term safety data are limited. Most trials follow participants for months, not years.
• Therapist training standards are inconsistent. The field is growing faster than training and certification.
• Psychological contraindications are real. People with a personal or family history of psychosis or bipolar disorder are usually excluded from trials.
• Physical effects matter. Rises in heart rate and blood pressure can be a concern, particularly for people who are medically unwell.
• Adverse experiences can occur. Difficult psychological experiences during sessions are common and, without adequate support, can be distressing or destabilizing.

“Expert clinical leadership warns that psychedelics are not a standalone solution due to tempered evidence and operational challenges.” — Becker’s Behavioral Health

These gaps are why psilocybin and MDMA belong in clinical research for now, with careful screening, monitoring and aftercare.

Why healing requires more than molecules

One thing gets lost in much of the excitement around psychedelic research: the molecule is not the therapy.

When people read about improvements after a single psilocybin session, the natural instinct is to focus on the substance. But the research model treats the substance as only one part of the intervention. The window that psychedelics may open is only as useful as the support around it.

Researchers increasingly argue that a standardized, emotionally safe context may matter as much as the compound, and part of the current scientific debate is exactly how much each contributes. That lesson applies to any treatment for depression or distress, including the ones available today: preparation, a trusted clinical relationship and ongoing follow-up make a real difference.

If you are drawn to this research because conventional treatments haven’t reached your pain, that instinct deserves respect. The best next step is usually a conversation with a clinician about the options that are available to you now.

Take the next step with evidence-based support

Mystic Health is a physician-led clinic in Santa Monica, California. We do not offer psilocybin, MDMA or other investigational psychedelics. What we do offer is built around whole-person care: ketamine-assisted psychotherapy, which uses ketamine off-label with preparation and integration, and Spravato, an FDA-approved esketamine nasal spray for treatment-resistant depression given in our REMS-certified clinic.

You can explore our clinical evidence library, where research on investigational compounds is clearly labelled as such. We also offer psychotherapy and psychiatry. For people navigating serious illness, our cancer and palliative care team offers palliative consultations, psycho-oncology and pain management, coordinated with your oncology team. When you’re ready, you can book a free discovery call.

Frequently asked questions

Recommended

• Innovative therapies for emotional healing: CBT to psychedelics
• What is psychedelic therapy? Guide to healing & mental health